About BIOCODEX
Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,600 employees, Biocodex generated net revenues of above €500 million in 2022, including 1/3 in France and 2/3 internationally. The group is present in 115 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.
|
|
|
1,001-5,000 employees
View all BIOCODEX employees
|
|
Pharmaceuticals
|
|
7 avenue Gallieni, GENTILLY, FR
|
|
1953
|
|
Women's Health, Gastroenterology, Rheumatology, Pain Management, Otolaryngology, Rheumatology, Neurology/Psychiatry, Pédiatry, Pediatry, Women's Health, Pain Management, Otolaryngology, Gastroenterology
|
BIOCODEX Alternatives
Frequently Asked Questions about BIOCODEX
Albert Maudens is the General Manager of BIOCODEX. To contact Albert Maudens email at [email protected] or [email protected].
BIOCODEX Staff Directory
Search BIOCODEX Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
